Navigation Links
Replidyne Announces 2007 Fourth Quarter and Full Year Results
Date:2/26/2008

er full year contingent supply agreement costs related to the faropenem program and $1.5 million of product acquisition cost in 2006 to complete the purchase of tRNA synthetase technology from GlaxoSmithKline which includes Replidyne's C. difficile program and REP8839.

Sales, general and administrative expenses for the fourth quarter of 2007 were $3.2 million compared to $3.5 million in the fourth quarter of 2006 reflecting lower marketing study expenses in the 2007 quarter. Included in the 2007 quarter result was $0.6 million related to the organizational restructuring implemented on December 10, 2007. Full year 2007 selling, general and administrative expenses were $13 million compared to $12.2 million in 2006 reflecting increased full year compensation costs, restructuring expense, and increased professional fees related to public company compliance.

Investment income for the fourth quarter of 2007 was $1.2 million compared to $1.7 million for the fourth quarter of 2006, primarily reflecting lower cash balances available for investment in the 2007 period. Full year 2007 investment income was $5.5 million compared to $6.0 million 2006.

As reported in its 2006 results, through July 3, 2006 Replidyne recorded dividends due to preferred shareholders of $5.4 million. All outstanding preferred stock and accumulated dividends were converted into common stock upon closing of the initial public offering on July 3, 2006 and no preferred stock or accrued dividends were outstanding after that date.

Conference Call Information

Replidyne will host a conference call and webcast today, February 26, 2008, at 4:45 P.M. EST to discuss 2007 fourth quarter and full year financial results and update the Company's expectations. Callers may participate in the conference call by dialing 866-510-0707 (domestic) or 617-597-5376 (international), and providing the passcode 33794809. To access the live webcast, log on to the Company's website at

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Xeno Diagnostics has again received an ... COLA inspection. Xeno has met all criteria for ... organization. Accreditation is earned only by laboratories that ... demonstrate continued accuracy in the performance of proficiency ... , While the Laboratory Excellence award ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary commercial focus on ... has been granted a Type C meeting with the ... meeting will be held in February 2015.  During this ...
(Date:12/15/2014)... Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology,  today celebrated continued positive ... exVive3D TM Human Liver Tissue.  The product, ... release on November 18, has been recognized as ... for innovation. Most recently, on December ...
(Date:12/13/2014)... Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite Canada, ... they have joined forces to support Canadian entrepreneurs tackling social ... Group Founder was at the MaRS Centre to announce the ... impact venture fund. This fund has $1 million in seed ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... Aug. 27 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... that Jerry McMahon, Ph.D., chairman and CEO,will present ... The Thomas Weisel Partners Healthcare Conference 2007 on ... the Four Seasons Hotel in Boston. BioCentury,s ...
... Pharmaceuticals Inc.,("Heritage") and Ipca Laboratories Ltd. ("Ipca") announced ... alliance for the development, supply and,marketing of generic ... the Agreement, Ipca shall develop and register selected,products ... and marketing,rights to such products. The parties shall ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a ... novel medicines for the treatment of,hepatitis C virus ... Ph.D. has been promoted to the position of ... Ph.D. who plans to pursue,other opportunities. Dr. Worland ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Participation in Upcoming Conferences 2Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products 2Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer 2Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer 3
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... The mating habits of marine turtle may help to protect ... research led by the University of Exeter. Published today (25 ... Society B , the study shows how the mating patterns ... them deal with the fact that global warming is leading ...
... Reston VA More than 7,000 toxicologists from every corner ... Toxicology (SOT) 51st Annual Meeting and ToxExpo, which will highlight ... ,The five-day meeting will take place at the Moscone Convention ... is the study of the adverse effects of chemical, physical ...
... at The University of Nottingham has taken us a step ... different environmental conditions and fight off attack from parasites. ... National Academy of Sciences of the United States of ... root growth in the plant Arabidopsis thaliana , or ...
Cached Biology News:Turtles' mating habits protect against effects of climate change 2Toxicologists' annual meeting in San Francisco to showcase the latest scientific achievements 2Improving crops from the roots up 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
The epitope is specific for TASK and is not present in any other known proteins tested so far.,SPECIES REACTIVITIES: The epitope is also highly conserved between mouse and rat (17/18 residues iden...
Rat Antibody to Kinase Suppressor Of Ras Recognises the kinase suppressor of Ras (KSR). Immunogen: Recombinant human KSR protein Specificity: human kinase supressor of Ras...
Request Info...
Biology Products: